IsoPlexis (ISO) Stock Price, News & Analysis

Company Overview

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.

Key Stats

• Today's Range: $0.76 to $0.76
• 50-Day Range: $0.74 to $1.13
• 52-Week Range: $0.60 to $5.10
• Volume: N/A
• Average Volume: 68,375 shs
• Market Capitalization: $30.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ISO Stock Analysis - Frequently Asked Questions

How were IsoPlexis' earnings last quarter?

IsoPlexis Co. (NASDAQ:ISO) posted its earnings results on Wednesday, November, 10th. The company reported ($10.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by $9.87. The firm earned $4.19 million during the quarter, compared to analyst estimates of $3.79 million. IsoPlexis had a negative net margin of 632.41% and a negative trailing twelve-month return on equity of 127.86%.

When did IsoPlexis IPO?

IsoPlexis (ISO) raised $125 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 8,333,000 shares at $14.00-$16.00 per share.

What other stocks do shareholders of IsoPlexis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IsoPlexis investors own include Biora Therapeutics (BIOR), NIO (NIO), PayPal (PYPL), Alibaba Group (BABA), Robinhood Markets (HOOD) and Lucid Group (LCID).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 8/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ISO
• CIK: 1615055
• Web: isoplexis.com
• Phone: 203-208-4111
• Fax: N/A
• Employees: 459
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$106 million
• Net Margins: -632.41%
• Pretax Margin: -632.40%
• Return on Equity: -127.86%
• Return on Assets: -71.41%

Debt

• Debt-to-Equity Ratio: 1.12
• Current Ratio: 4.06
• Quick Ratio: 2.50

Sales & Book Value

• Annual Sales: $16.76 million
• Price / Sales: 1.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.04 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 39,760,000
• Free Float: 37,218,000
• Market Cap: $30.28 million
• Optionable: Not Optionable
• Beta: 1.32